Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,175.63
(
0.15%
)
US TECH 100
26,560.00
(
0.02%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
101.98
(
0.44%
)
Bitcoin
76,711.55
(
-2.47%
)
News Focus
News Focus
Post# of 257448
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122891
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 41494

Friday, 02/02/2007 12:29:54 PM

Friday, February 02, 2007 12:29:54 PM

Post# of 257448
> vrtx will have plenty of naive trial data that is not tainted by more than one investigational compound<

Not sure I agree here.

If there were a safety problem in a combination trial with VX-950 in the treatment-refractory setting, why do you assume that there would be no taint to affect VX-950 development in the treatment-naïve setting? Even the ~1,000 patients that will have been tested in the treatment-naïve setting are not a lot of patients when it comes to detecting rare side effects.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today